Article

Phase III dry eye treatment study completed

ProTrials Research has completed a large phase III clinical study examining the safety and effectiveness of a new treatment for dry eye disease.

 

Sunnyvale, CA-ProTrials Research has completed a large phase III clinical study examining the safety and effectiveness of a new treatment for dry eye disease.

In the last 3 years, ProTrials has conducted four phase III dry eye studies, and multiple phase III trials across a broad range of therapeutic areas involving over 100 sites and 1,000 patients, according to the company.

“ProTrials offers experience in many therapeutic areas, but our ability to handle the intricacies required in ophthalmology studies is key to our repeated success in this type of research,” said Inger Arum, president of ProTrials.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.